A Medicine That Treats Mania Also Shows Effectiveness in Treating Depression in Bipolar Disorder

Cariprazine, a medicine approved by the FDA in 2015 for the treatment of manic episodes in bipolar I disorder, was effective in reducing depressive symptoms in bipolar I disorder patients in a phase 3 clinical trial reported March 8, 2019 in the American Journal of Psychiatry.

The medicine, sold under the brand name of Vraylar in the U.S., interacts with specific receptors for dopamine and serotonin in the brain. In the class of “atypical” or second-generation antipsychotic medicines, it has been used primarily to treat people with schizophrenia and bipolar mania.

Click here to read the full article.